Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
伊布替尼联合苯达莫司汀和利妥昔单抗治疗复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者的3期HELIOS研究的最终5年结果
期刊:Leukemia & Lymphoma
影响因子:2.2
doi:10.1080/10428194.2020.1795159
Fraser, Graeme A M; Chanan-Khan, Asher; Demirkan, Fatih; Santucci Silva, Rodrigo; Grosicki, Sebastian; Janssens, Ann; Mayer, Jiri; Bartlett, Nancy L; Dilhuydy, Marie-Sarah; Loscertales, Javier; Avigdor, Abraham; Rule, Simon; Samoilova, Olga; Pavlovsky, Miguel A; Goy, Andre; Mato, Anthony; Hallek, Michael; Salman, Mariya; Tamegnon, Monelle; Sun, Steven; Connor, Anne; Nottage, Kerri; Schuier, Natasha; Balasubramanian, Sriram; Howes, Angela; Cramer, Paula
